^
Association details:
| Biomarker: | MYC rearrangement + LDH elevation |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Regimen: | (vincristine + Rituxan (rituximab) + doxorubicin hydrochloride + prednisone + cyclophosphamide + etoposide IV) |
| Direction: | Resistant |
Evidence:
Source:
Title:
NO DIFFERENCE IN OVERALL SURVIVAL BETWEEN R-CHOP AND R-EPOCH AMONG PATIENTS WITH ADVANCED STAGE MYC-REARRANGED, DOUBLE HIT, OR TRIPLE HIT DIFFUSE LARGE B-CELL LYMPHOMA
Published date:
05/12/2021
Excerpt:
Only patients with MYC-R/DHL/THL who received R-CHOP or R-EPOCH as a first-line therapy were included in the analysis…. Among entire MYC-R cohort, univariate analysis of treatment type (R-CHOP, R-EPOCH), age ≥60y, sex, race, ECOG ≥2, elevated LDH, and >1 extra-nodal site, only ECOG ≥2 (p = <0.001) and elevated LDH (p = 0.041) were significant for worse mortality. By multivariate analysis, ECOG ≥2 (HR 2.59 [1.317-5.1]) and elevated LDH (HR 1.61 [1.016-2.6]) were again the only significant variables associated with risk of mortality.
